Jun Nakayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jun Nakayama has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
Yoshiko Sato
Department of Molecular Pathology Shinshu University School of Medicine Matsumoto Japan
7 shared publications- Masatomo Kawakubo
Department of Molecular Pathology Shinshu University School of Medicine Matsumoto Japan
6 shared publications - Chifumi Fujii
Department of Molecular Pathology Shinshu University School of Medicine Matsumoto Japan
5 shared publications Minoru Fukuda
Tumor Microenvironment and Cancer Immunology Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
5 shared publications- Naoki Tanaka
Department of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan
5 shared publications Hisanori Matoba
Department of Molecular Pathology, Shinshu University School of Medicine, Matsumoto, Japan
4 shared publications
Latest Publications
- 28 July 2026
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (11) , 2438-2452
A4gnt-Deficient Mice Show Enhanced IL-11 Receptor α–Glycoprotein 130–Janus Kinase 2–STAT3 Signaling in Early Stages of Gastric Tumorigenesis
- 28 July 2026
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (11) , 2438-2452
A4gnt-Deficient Mice Show Enhanced IL-11 Receptor α–Glycoprotein 130–Janus Kinase 2–STAT3 Signaling in Early Stages of Gastric Tumorigenesis
- Open Access
- 16 June 2026
- Published by Wiley in Pathology International
- Vol. 76 (6) , e70137
Human Intestinal Spirochetosis Shows Higher Positivity in Sessile Serrated Lesions Than in Tubular Adenomas With Preferential Colonization of Absorptive Epithelium
Factors underlying differential colonization by human intestinal spirochetosis (HIS) of various colorectal neoplastic lesions remain unclear. We compared HIS positivity and colonization patterns between sessile serrated lesions (SSLs) and tubular adenomas (TAs) and examined the relationship between spirochetal distribution and epithelial differentiation. HIS positivity was significantly higher in SSLs than TAs at both lesion (26/590 [4.4%] vs. 3/536 [0.6%], p < 0.001) and case (16/421 [3.8%] vs. 1/171 [0.6%], p = 0.03) levels. Because the SSL and TA main cohorts covered different periods, nine HIS‐positive SSL cases harboring TAs diagnosed outside the TA cohort period were separately analyzed for within‐case comparison, confirming significantly higher HIS positivity in SSLs than TAs (11/12 [91.7%] vs. 6/23 [26.1%], p = 0.003). Among HIS‐positive lesions, both SSLs and TAs showed reduced colonization at lesion sites compared to surrounding mucosa, with greater reduction in TAs. GS‐II staining demonstrated reduced terminal βGlcNAc on HIS bacterial bodies at SSL lesion sites. HIS preferentially colonized absorptive epithelium, although less evidently in TAs with limited absorptive differentiation. All cases harbored only Brachyspira aalborgi . These results indicate that HIS exhibits universal affinity for absorptive epithelium and that higher HIS positivity in SSLs reflects their greater abundance of absorptive epithelium.
- 16 June 2026
- Published by Wiley in Pathology International
- Vol. 76 (6) , e70137
Open AccessHuman Intestinal Spirochetosis Shows Higher Positivity in Sessile Serrated Lesions Than in Tubular Adenomas With Preferential Colonization of Absorptive Epithelium
Factors underlying differential colonization by human intestinal spirochetosis (HIS) of various colorectal neoplastic lesions remain unclear. We compared HIS positivity and colonization patterns between sessile serrated lesions (SSLs) and tubular adenomas (TAs) and examined the relationship between spirochetal distribution and epithelial differentiation. HIS positivity was significantly higher in SSLs than TAs at both lesion (26/590 [4.4%] vs. 3/536 [0.6%], p < 0.001) and case (16/421 [3.8%] vs. 1/171 [0.6%], p = 0.03) levels. Because the SSL and TA main cohorts covered different periods, nine HIS‐positive SSL cases harboring TAs diagnosed outside the TA cohort period were separately analyzed for within‐case comparison, confirming significantly higher HIS positivity in SSLs than TAs (11/12 [91.7%] vs. 6/23 [26.1%], p = 0.003). Among HIS‐positive lesions, both SSLs and TAs showed reduced colonization at lesion sites compared to surrounding mucosa, with greater reduction in TAs. GS‐II staining demonstrated reduced terminal βGlcNAc on HIS bacterial bodies at SSL lesion sites. HIS preferentially colonized absorptive epithelium, although less evidently in TAs with limited absorptive differentiation. All cases harbored only Brachyspira aalborgi . These results indicate that HIS exhibits universal affinity for absorptive epithelium and that higher HIS positivity in SSLs reflects their greater abundance of absorptive epithelium.
- 8 January 2024
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 72 (2) , 71-78
Identification of Terminal βGlcNAc on Brachyspira Species in Human Intestinal Spirochetosis
Human intestinal spirochetosis (HIS) is a colorectal bacterial infection caused by the Brachyspira species. Griffonia simplicifolia-II (GS-II) is a lectin specific to terminal α/βGlcNAc residues. Here, we investigated terminal βGlcNAc residues in the context of HIS infection using GS-II-horseradish peroxidase staining and HIK1083 immunostaining specific to terminal αGlcNAc residues. Fourteen of 15 HIS cases were GS-II-positive on the bacterial body. No cases showed HIK1083 positivity. The percentage of bacterial bodies staining positively for GS-II based on comparison with anti- Treponema immunostaining was ≤30% in seven cases, 30–70% in two, and >70% in six. Of 15 HIS cases analyzed, none were comorbid with tubular adenomas, and three were comorbid with sessile serrated lesions (SSLs). To determine the species of spirochete infected, the B. aalborgi-specific or B. pilosicoli-specific NADPH oxidase genes were amplified by PCR. After direct sequencing of the PCR products, all nine cases in which PCR products were observed were found to be infected with B. aalborgi alone. These results indicate that the HIS bacterial body, especially of B. aalborgi, is characterized by terminal βGlcNAc and also indicate that terminal βGlcNAc on the HIS bacterial body is associated with HIS preference for SSLs:
- 8 January 2024
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 72 (2) , 71-78
Identification of Terminal βGlcNAc on Brachyspira Species in Human Intestinal Spirochetosis
Human intestinal spirochetosis (HIS) is a colorectal bacterial infection caused by the Brachyspira species. Griffonia simplicifolia-II (GS-II) is a lectin specific to terminal α/βGlcNAc residues. Here, we investigated terminal βGlcNAc residues in the context of HIS infection using GS-II-horseradish peroxidase staining and HIK1083 immunostaining specific to terminal αGlcNAc residues. Fourteen of 15 HIS cases were GS-II-positive on the bacterial body. No cases showed HIK1083 positivity. The percentage of bacterial bodies staining positively for GS-II based on comparison with anti- Treponema immunostaining was ≤30% in seven cases, 30–70% in two, and >70% in six. Of 15 HIS cases analyzed, none were comorbid with tubular adenomas, and three were comorbid with sessile serrated lesions (SSLs). To determine the species of spirochete infected, the B. aalborgi-specific or B. pilosicoli-specific NADPH oxidase genes were amplified by PCR. After direct sequencing of the PCR products, all nine cases in which PCR products were observed were found to be infected with B. aalborgi alone. These results indicate that the HIS bacterial body, especially of B. aalborgi, is characterized by terminal βGlcNAc and also indicate that terminal βGlcNAc on the HIS bacterial body is associated with HIS preference for SSLs:
- Open Access
Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors
Non-alcoholic steatohepatitis (NASH), which is the most severe manifestation of non-alcoholic fatty liver disease (NAFLD), has been recognized as a major hepatocellular carcinoma (HCC) catalyst. However, the molecular mechanism of NASH-liver fibrosis-HCC sequence remains unclear and a specific and effective treatment for NASH has not yet been established. The progress in this field depends on the availability of reliable preclinical models which show the steady progression to NASH, liver cirrhosis, and HCC. However, most of the NASH mouse models that have been described to date develop NASH generally for more than 24 weeks and there is an uncertainty of HCC development. To overcome such shortcomings of experimental NASH studies, we established a novel NASH-HCC mouse model with very high reproducibility, generality, and convenience. We treated male C57BL/6J mice with a newly developed choline-deficient and methionine-restricted high-fat diet, named OYC-NASH2 diet, for 60 weeks. Treatment of OYC-NASH2 diet for 3 weeks revealed marked steatosis, lobular inflammation, and fibrosis, histologically diagnosed as NASH. Liver cirrhosis was observed in all mice with 48-week treatment. Liver nodules emerged at 12 weeks of the treatment, > 2 mm diameter liver tumors developed in all mice at 24 weeks of the treatment and HCC appeared after 36-week treatment. In conclusion, our rapidly progressive and highly reproducible NASH-liver cirrhosis-HCC model is helpful for preclinical development and research on the pathogenesis of human NAFLD-NASH-HCC. Our mouse model would be useful for the development of novel chemicals for NASH-HCC-targeted therapies.
Open AccessEstablishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors
Non-alcoholic steatohepatitis (NASH), which is the most severe manifestation of non-alcoholic fatty liver disease (NAFLD), has been recognized as a major hepatocellular carcinoma (HCC) catalyst. However, the molecular mechanism of NASH-liver fibrosis-HCC sequence remains unclear and a specific and effective treatment for NASH has not yet been established. The progress in this field depends on the availability of reliable preclinical models which show the steady progression to NASH, liver cirrhosis, and HCC. However, most of the NASH mouse models that have been described to date develop NASH generally for more than 24 weeks and there is an uncertainty of HCC development. To overcome such shortcomings of experimental NASH studies, we established a novel NASH-HCC mouse model with very high reproducibility, generality, and convenience. We treated male C57BL/6J mice with a newly developed choline-deficient and methionine-restricted high-fat diet, named OYC-NASH2 diet, for 60 weeks. Treatment of OYC-NASH2 diet for 3 weeks revealed marked steatosis, lobular inflammation, and fibrosis, histologically diagnosed as NASH. Liver cirrhosis was observed in all mice with 48-week treatment. Liver nodules emerged at 12 weeks of the treatment, > 2 mm diameter liver tumors developed in all mice at 24 weeks of the treatment and HCC appeared after 36-week treatment. In conclusion, our rapidly progressive and highly reproducible NASH-liver cirrhosis-HCC model is helpful for preclinical development and research on the pathogenesis of human NAFLD-NASH-HCC. Our mouse model would be useful for the development of novel chemicals for NASH-HCC-targeted therapies.
- Open Access
- 2 May 2023
- Published by MDPI AG in Preprints.org
Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing Into Liver Cirrhosis and Tumors
Non-alcoholic steatohepatitis (NASH), which is the most severe manifestation of non-alcoholic fatty liver disease (NAFLD), has been recognized as a major hepatocellular carcinoma (HCC) catalyst. However, the molecular mechanism of NAFLD-NASH-HCC sequence remains unclear and a specific and effective treatment for NASH has not yet been established. The progress in this field depends on the availability of reliable preclinical models which show the steady progress to NASH, liver cirrhosis, and HCC. However, most of NASH mouse models that have been described to date develop NASH generally for more than 24 weeks and there is an uncertainty of HCC development. To overcome such shortcomings of experimental NASH studies, we established a novel NASH-HCC mouse model with very high reproducibility, generality, and convenience. We treated male C57BL/6J mice with a newly developed choline-deficient and methionine-restricted high-fat diet (CDMRHFD) for 60 weeks. Treatment of CDMRHFD for 3 weeks revealed marked steatosis, lobular inflammation, and fibrosis, histologically diagnosed as NASH. Liver cirrhosis was observed in all mice with 36-week treatment. Liver nodule emerged at 12 weeks of the treatment, and diameter >2 mm liver tumors developed in all mice at 24 weeks of the treatment. In conclusion, our rapidly progressive and highly reproducible NASH-liver cirrhosis-HCC model is helpful for preclinical development and research on the pathogenesis of human NAFLD-NASH-HCC. Our mouse model would be useful for the development of novel chemistry for NASH-HCC-targeted therapies or HCC prevention strategies.
- 2 May 2023
- Published by MDPI AG in Preprints.org
Open AccessEstablishment of Novel Mouse Model of Dietary NASH Rapidly Progressing Into Liver Cirrhosis and Tumors
Non-alcoholic steatohepatitis (NASH), which is the most severe manifestation of non-alcoholic fatty liver disease (NAFLD), has been recognized as a major hepatocellular carcinoma (HCC) catalyst. However, the molecular mechanism of NAFLD-NASH-HCC sequence remains unclear and a specific and effective treatment for NASH has not yet been established. The progress in this field depends on the availability of reliable preclinical models which show the steady progress to NASH, liver cirrhosis, and HCC. However, most of NASH mouse models that have been described to date develop NASH generally for more than 24 weeks and there is an uncertainty of HCC development. To overcome such shortcomings of experimental NASH studies, we established a novel NASH-HCC mouse model with very high reproducibility, generality, and convenience. We treated male C57BL/6J mice with a newly developed choline-deficient and methionine-restricted high-fat diet (CDMRHFD) for 60 weeks. Treatment of CDMRHFD for 3 weeks revealed marked steatosis, lobular inflammation, and fibrosis, histologically diagnosed as NASH. Liver cirrhosis was observed in all mice with 36-week treatment. Liver nodule emerged at 12 weeks of the treatment, and diameter >2 mm liver tumors developed in all mice at 24 weeks of the treatment. In conclusion, our rapidly progressive and highly reproducible NASH-liver cirrhosis-HCC model is helpful for preclinical development and research on the pathogenesis of human NAFLD-NASH-HCC. Our mouse model would be useful for the development of novel chemistry for NASH-HCC-targeted therapies or HCC prevention strategies.
- Open Access
- 27 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 384
Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
Non-alcoholic steatohepatitis (NASH) is a chronic liver disease which may progress into liver fibrosis and cancer. Since NASH patients have a high prevalence of atherosclerosis and ensuing cardiovascular diseases, simultaneous management of NASH and atherosclerosis is required. Currently, rodents are the most common animal models for NASH and accompanying liver fibrosis, but there are great differences in lipoprotein profiles between rodents and humans, which makes it difficult to reproduce the pathology of NASH patients with atherosclerosis. Rabbits can be a promising candidate for assessing NASH and atherosclerosis because lipoprotein metabolism is more similar to humans compared with rodents. To develop the NASH model using rabbits, we treated the Japanese White rabbit with a newly developed high-fat high-cholesterol diet (HFHCD) containing palm oil 7.5%, cholesterol 0.5%, and ferrous citrate 0.5% for 16 weeks. HFHCD-fed rabbits exhibited NASH at 8 weeks after commencing the treatment and developed advanced fibrosis by the 14th week of treatment. In addition to hypercholesterolemia, atherosclerotic lesion developed in the aorta after 8 weeks. Therefore, this rabbit NASH model might contribute to exploring the concurrent treatment options for human NASH and atherosclerosis.
- 27 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 384
Open AccessDevelopment of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
Non-alcoholic steatohepatitis (NASH) is a chronic liver disease which may progress into liver fibrosis and cancer. Since NASH patients have a high prevalence of atherosclerosis and ensuing cardiovascular diseases, simultaneous management of NASH and atherosclerosis is required. Currently, rodents are the most common animal models for NASH and accompanying liver fibrosis, but there are great differences in lipoprotein profiles between rodents and humans, which makes it difficult to reproduce the pathology of NASH patients with atherosclerosis. Rabbits can be a promising candidate for assessing NASH and atherosclerosis because lipoprotein metabolism is more similar to humans compared with rodents. To develop the NASH model using rabbits, we treated the Japanese White rabbit with a newly developed high-fat high-cholesterol diet (HFHCD) containing palm oil 7.5%, cholesterol 0.5%, and ferrous citrate 0.5% for 16 weeks. HFHCD-fed rabbits exhibited NASH at 8 weeks after commencing the treatment and developed advanced fibrosis by the 14th week of treatment. In addition to hypercholesterolemia, atherosclerotic lesion developed in the aorta after 8 weeks. Therefore, this rabbit NASH model might contribute to exploring the concurrent treatment options for human NASH and atherosclerosis.
- 15 September 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (6) , 1173-1179
TAK1 Limits Death Receptor Fas-Induced Proinflammatory Cell Death in Macrophages
Fas, a member of the death receptor family, plays a central role in initiating cell death, a biological process crucial for immune homeostasis. However, the immunological and pathophysiological impacts to which enhanced Fas signaling gives rise remain to be fully understood. Here we demonstrate that TGF-β–activated kinase 1 (TAK1) works as a negative regulator of Fas signaling in macrophages. Upon Fas engagement with high concentrations of FasL, mouse primary macrophages underwent cell death, and, surprisingly, Fas stimulation led to proteolytic cleavage of gasdermin (GSDM) family members GSDMD and GSDME, a hallmark of pyroptosis, in a manner dependent on caspase enzymatic activity. Remarkably, TAK1-deficient macrophages were highly sensitive to even low concentrations of FasL. Mechanistically, TAK1 negatively modulated RIPK1 kinase activity to protect macrophages from excessive cell death. Intriguingly, mice deficient for TAK1 in macrophages (TAK1mKO mice) spontaneously developed tissue inflammation, and, more important, the emergence of inflammatory disease symptoms was markedly diminished in TAK1mKO mice harboring a catalytically inactive RIPK1. Taken together, these findings not only revealed an unappreciated role of TAK1 in Fas-induced macrophage death but provided insight into the possibility of perturbation of immune homeostasis driven by aberrant cell death.
- 15 September 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (6) , 1173-1179
TAK1 Limits Death Receptor Fas-Induced Proinflammatory Cell Death in Macrophages
Fas, a member of the death receptor family, plays a central role in initiating cell death, a biological process crucial for immune homeostasis. However, the immunological and pathophysiological impacts to which enhanced Fas signaling gives rise remain to be fully understood. Here we demonstrate that TGF-β–activated kinase 1 (TAK1) works as a negative regulator of Fas signaling in macrophages. Upon Fas engagement with high concentrations of FasL, mouse primary macrophages underwent cell death, and, surprisingly, Fas stimulation led to proteolytic cleavage of gasdermin (GSDM) family members GSDMD and GSDME, a hallmark of pyroptosis, in a manner dependent on caspase enzymatic activity. Remarkably, TAK1-deficient macrophages were highly sensitive to even low concentrations of FasL. Mechanistically, TAK1 negatively modulated RIPK1 kinase activity to protect macrophages from excessive cell death. Intriguingly, mice deficient for TAK1 in macrophages (TAK1mKO mice) spontaneously developed tissue inflammation, and, more important, the emergence of inflammatory disease symptoms was markedly diminished in TAK1mKO mice harboring a catalytically inactive RIPK1. Taken together, these findings not only revealed an unappreciated role of TAK1 in Fas-induced macrophage death but provided insight into the possibility of perturbation of immune homeostasis driven by aberrant cell death.
- Open Access
- 31 August 2022
- Published by Wiley in Cancer Science
- Vol. 113 (11) , 3852-3863
α1,4‐Linked N ‐acetylglucosamine suppresses gastric cancer development by inhibiting Mucin‐1‐mediated signaling
Gastric cancer is the second leading cause of cancer deaths worldwide, and more understanding of its molecular basis is urgently needed. Gastric gland mucin secreted from pyloric gland cells, mucous neck cells, and cardiac gland cells of the gastric mucosa harbors unique O-glycans carrying terminal alpha 1,4-linked N-acetylglucosamine (alpha GlcNAc) residues. We previously reported that alpha GlcNAc loss correlated positively with poor outcomes for patients with differentiated-type gastric cancer. However, the molecular mechanisms underlying these outcomes remained poorly understood. Here, we examined the effects of upregulated alpha GlcNAc expression on malignant phenotypes of the differentiated-type gastric cancer cell lines, AGS and MKN7. Upregulation of alpha GlcNAc following ectopic expression of its biosynthetic enzyme attenuated cell proliferation, motility, and invasiveness of AGS and MKN7 cells in vitro. Moreover, AGS cell tumorigenicity was significantly suppressed by alpha GlcNAc overexpression in a xenograft model. To define the molecular mechanisms underlying these phenotypes, we investigated alpha GlcNAc binding proteins in AGS cells and identified Mucin-1 (MUC1) and podocalyxin. Both proteins were colocalized with alpha GlcNAc on human gastric cancer cells. We also found that alpha GlcNAc was bound to MUC1 in murine normal gastric mucosa. When we assessed the effects of alpha GlcNAc binding to MUC1, we found that alpha GlcNAc blocked galectin-3 binding to MUC1, phosphorylation of the MUC1 C-terminus, and recruitment of Src and beta-catenin to that C-terminus. These results suggest that alpha GlcNAc regulates cancer cell phenotypes by dampening MUC1 signal transduction.
- 31 August 2022
- Published by Wiley in Cancer Science
- Vol. 113 (11) , 3852-3863
Open Accessα1,4‐Linked N ‐acetylglucosamine suppresses gastric cancer development by inhibiting Mucin‐1‐mediated signaling
Gastric cancer is the second leading cause of cancer deaths worldwide, and more understanding of its molecular basis is urgently needed. Gastric gland mucin secreted from pyloric gland cells, mucous neck cells, and cardiac gland cells of the gastric mucosa harbors unique O-glycans carrying terminal alpha 1,4-linked N-acetylglucosamine (alpha GlcNAc) residues. We previously reported that alpha GlcNAc loss correlated positively with poor outcomes for patients with differentiated-type gastric cancer. However, the molecular mechanisms underlying these outcomes remained poorly understood. Here, we examined the effects of upregulated alpha GlcNAc expression on malignant phenotypes of the differentiated-type gastric cancer cell lines, AGS and MKN7. Upregulation of alpha GlcNAc following ectopic expression of its biosynthetic enzyme attenuated cell proliferation, motility, and invasiveness of AGS and MKN7 cells in vitro. Moreover, AGS cell tumorigenicity was significantly suppressed by alpha GlcNAc overexpression in a xenograft model. To define the molecular mechanisms underlying these phenotypes, we investigated alpha GlcNAc binding proteins in AGS cells and identified Mucin-1 (MUC1) and podocalyxin. Both proteins were colocalized with alpha GlcNAc on human gastric cancer cells. We also found that alpha GlcNAc was bound to MUC1 in murine normal gastric mucosa. When we assessed the effects of alpha GlcNAc binding to MUC1, we found that alpha GlcNAc blocked galectin-3 binding to MUC1, phosphorylation of the MUC1 C-terminus, and recruitment of Src and beta-catenin to that C-terminus. These results suggest that alpha GlcNAc regulates cancer cell phenotypes by dampening MUC1 signal transduction.
- Open Access
- 22 November 2021
- Published by Wiley in Cancer Science
- Vol. 113 (2) , 576-586
Glycosylation of MUC6 by α1,4‐linked N‐acetylglucosamine enhances suppression of pancreatic cancer malignancy
Biomarkers for early diagnosis of pancreatic cancer are greatly needed, as the high fatality of this cancer is in part due to delayed detection. α1,4‐linked N‐acetylglucosamine (αGlcNAc), a unique O‐glycan specific to gastric gland mucus, is biosynthesized by α1,4‐N‐acetylglucosaminyltransferase (α4GnT) and primarily bound at the terminal glycosylated residue to scaffold protein MUC6. We previously reported that αGlcNAc expression decreases at early stages of neoplastic pancreatic lesions, followed by decreased MUC6 expression, although functional effects of these outcomes were unknown. Here, we ectopically expressed α4GnT, the αGlcNAc biosynthetic enzyme, together with MUC6 in the human pancreatic cancer cell lines MIA PaCa‐2 and PANC‐1, neither of which expresses α4GnT and MUC6. We observed significantly suppressed proliferation in both lines following coexpression of α4GnT and MUC6. Moreover, cellular motility decreased following MUC6 ectopic expression, an effect enhanced by cotransduction with α4GnT. MUC6 expression also attenuated invasiveness of both lines relative to controls, and this effect was also enhanced by additional α4GnT expression. We found αGlcNAc‐bound MUC6 formed a complex with trefoil factor 2. Furthermore, analysis of survival curves of patients with pancreatic ductal adenocarcinoma using a gene expression database showed that samples marked by higher A4GNT or MUC6 mRNA levels were associated with relatively favorable prognosis. These results strongly suggest that αGlcNAc and MUC6 function as tumor suppressors in pancreatic cancer and that decreased expression of both may serve as a biomarker of tumor progression to pancreatic cancer.
- 22 November 2021
- Published by Wiley in Cancer Science
- Vol. 113 (2) , 576-586
Open AccessGlycosylation of MUC6 by α1,4‐linked N‐acetylglucosamine enhances suppression of pancreatic cancer malignancy
Biomarkers for early diagnosis of pancreatic cancer are greatly needed, as the high fatality of this cancer is in part due to delayed detection. α1,4‐linked N‐acetylglucosamine (αGlcNAc), a unique O‐glycan specific to gastric gland mucus, is biosynthesized by α1,4‐N‐acetylglucosaminyltransferase (α4GnT) and primarily bound at the terminal glycosylated residue to scaffold protein MUC6. We previously reported that αGlcNAc expression decreases at early stages of neoplastic pancreatic lesions, followed by decreased MUC6 expression, although functional effects of these outcomes were unknown. Here, we ectopically expressed α4GnT, the αGlcNAc biosynthetic enzyme, together with MUC6 in the human pancreatic cancer cell lines MIA PaCa‐2 and PANC‐1, neither of which expresses α4GnT and MUC6. We observed significantly suppressed proliferation in both lines following coexpression of α4GnT and MUC6. Moreover, cellular motility decreased following MUC6 ectopic expression, an effect enhanced by cotransduction with α4GnT. MUC6 expression also attenuated invasiveness of both lines relative to controls, and this effect was also enhanced by additional α4GnT expression. We found αGlcNAc‐bound MUC6 formed a complex with trefoil factor 2. Furthermore, analysis of survival curves of patients with pancreatic ductal adenocarcinoma using a gene expression database showed that samples marked by higher A4GNT or MUC6 mRNA levels were associated with relatively favorable prognosis. These results strongly suggest that αGlcNAc and MUC6 function as tumor suppressors in pancreatic cancer and that decreased expression of both may serve as a biomarker of tumor progression to pancreatic cancer.